PEOPLE ON THE MOVE
Baxalta
Baxalta, an orphan disease bioharma, has appointed Karen Ferrante and Francois Nader to the Board of Directors.
Ferrante has worked for more than 20 years in oncology drug development, serving as Chief Medical Officer and head of R&D at Tokai during the firm’s IPO in September 2014. Before Tokai, he spent six years at Takeda and its oncology company Millennium, most recently as head of Oncology.
Nader joins the Baxalta board with 30 years of pharma experience. He led NPS Pharmaceuticals as CEO after several years as Chief Operating Officer and Chief Medical and Commercial Officer. He has also worked at Care Capital, Aventis, and Pasteur Vaccines within Rhone-Poulenc.
